Daiichi Sankyo
Daiichi Sankyo Company, Limited, commonly referred to as Daiichi Sankyo, is a prominent global pharmaceutical firm headquartered in Tokyo, Japan. Founded in 1899, the company has established a strong presence in major operational regions, including North America, Europe, and Asia, focusing on innovative healthcare solutions. Specialising in the research, development, and manufacturing of pharmaceuticals, Daiichi Sankyo is particularly renowned for its contributions to oncology, cardiovascular, and vaccine development. The company’s unique approach combines cutting-edge science with a commitment to improving patient outcomes, positioning it as a leader in the pharmaceutical industry. With a rich history marked by key milestones, Daiichi Sankyo has achieved notable success, including the development of groundbreaking therapies that have transformed treatment paradigms. Its dedication to innovation and quality has solidified its reputation as a trusted name in healthcare worldwide.
DitchCarbon Score
How does Daiichi Sankyo's carbon action stack up? DitchCarbon scores companies based on their carbon action and commitment to reducing emissions. Read about our methodology to learn more.
Industry Average
Mean score of companies in the Medical Device Manufacturing industry. Comparing a company's score to the industry average can give you a sense of how well the company is doing compared to its peers.
Industry Benchmark
Daiichi Sankyo's score of 33 is higher than 88% of the industry. This can give you a sense of how well the company is doing compared to its peers.
Daiichi Sankyo's reported carbon emissions
In 2023, Daiichi Sankyo reported total carbon emissions of approximately 4,602,874,000 kg CO2e globally, with emissions from Scope 1 at about 85,245,000 kg CO2e, Scope 2 at approximately 23,994,000 kg CO2e, and Scope 3 emissions reaching around 3,887,790,000 kg CO2e. The company has not disclosed specific reduction targets or initiatives under the Science Based Targets initiative (SBTi) or other climate pledges. In previous years, Daiichi Sankyo's emissions have shown significant figures, such as in 2021, where total emissions were about 2,318,000,000 kg CO2e, with Scope 1 and 2 emissions combined at approximately 109,735,000 kg CO2e. The company has consistently reported emissions across all three scopes, indicating a comprehensive approach to tracking its carbon footprint. Daiichi Sankyo's commitment to addressing climate change is evident through its detailed emissions reporting, although specific reduction targets or initiatives have not been outlined. The company operates within a challenging industry context, where pharmaceutical companies are increasingly pressured to reduce their carbon emissions and enhance sustainability practices.
Unlock detailed emissions data
Access structured emissions data, company-specific emission factors, and source documents
| 2012 | 2013 | 2014 | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Scope 1 | 217,257,000 | 000,000,000 | 000,000,000 | 000,000,000 | 000,000,000 | 000,000,000 | 000,000,000 | 00,000,000 | 00,000,000 | 00,000,000 | 00,000,000 | 00,000,000 |
| Scope 2 | 304,293,000 | 000,000,000 | 000,000,000 | 000,000,000 | 000,000,000 | 000,000,000 | 000,000,000 | 00,000,000 | 00,000,000 | 000,000,000 | 00,000,000 | 00,000,000 |
| Scope 3 | - | - | - | - | - | 000,000,000 | 000,000,000 | 000,000,000 | 0,000,000,000 | 000,000,000 | 0,000,000,000 | 0,000,000,000 |
Industry emissions intensity
Location emissions intensity
Reduction initiatives & disclosure networks
Companies disclose and commit to reducing emissions to show they are serious about reducing emissions impact over time. They can also help a company track its progress over time.
Daiichi Sankyo is not committed to any reduction initiatives we track. This may change over time as the company engages with new initiatives or updates its commitments. DitchCarbon will update this information as it becomes available.
